Innovative therapeutics

Investors

IR Snapshot

NASDAQBMRN
Beta1.72
Shares Outstanding175.6M
Average Volume (10 days)1.3M
Qtrly Dividend (Ann. Yield)-- (--)

Per Share Data

Earnings (TTM)($0.88)
Sales (TTM)$5.44
Book Value (MRQ)$16.02
Cash Flow (TTM)($0.14)
Cash (MRQ)$7.18

Analyst Views

Current Mean RecommendationStrong Buy
Strong Buy16
 
Buy2
 
Hold2
 
Underperform0
 
Sell0
 

Recent Insider Transactions

Jean-Jacques Bienaime
Director, Chief Executive Officer
(10,000)
Sell
Jan 5, 2018
V. Bryan Lawlis
(3,750)
Sell
Jan 2, 2018
Henry J. Fuchs
President, Worldwide R&D
(15,000)
Sell
Jan 2, 2018
Jean-Jacques Bienaime
Director, Chief Executive Officer
(10,000)
Sell
Dec 29, 2017
Jean-Jacques Bienaime
Director, Chief Executive Officer
(10,000)
Sell
Dec 28, 2017

Recent SEC Filings

Insider Buy/Sell
Jan 9, 2018
Insider Buy/Sell
Jan 4, 2018
Insider Buy/Sell
Jan 4, 2018
Insider Buy/Sell
Jan 2, 2018
Insider Buy/Sell
Dec 18, 2017

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information